Posted by Michael Wonder on 07 Apr 2021
FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer
7 April 2021 - Today the FDA granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics) for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
In April 2020, sacituzumab govitecan received accelerated approval for patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.
